Literature DB >> 8289698

The synaptic organization of the neocortex in Alzheimer's disease.

E Masliah1, A Miller, R D Terry.   

Abstract

Alzheimer's disease (AD) is characterized by a progressive deterioration of cognitive functions. Recent studies have shown that, in addition to the classically described lesions (plaques and tangles) found in AD, this neurodegenerative disorder is characterized by neuronal and synaptic loss and by synapto-axonal pathology. Stepwise regression analysis has shown that the major correlate of cognitive deficiency is the synapse loss in the prefrontal cortex, contributing about 70% of the strength of the correlation with global psychometric tests. We review evidence that supports the theory that most of the synaptic loss in the neocortex is derived from loss of cortico-cortical associational input into the modules. This hypothesis also predicts that neuritic plaque formation in the neocortical modules could represent an aberrant sprouting reaction of associational fibers responding to abnormal growth stimuli or to local damage. On these bases, it is also proposed that the cellular substrate of AD pathology is synapto-axonal, while in certain other forms of dementia such as Creutzfeldt-Jacob disease (CJD) and HIV encephalitis (HIVE) it is primarily dendritic.

Entities:  

Mesh:

Year:  1993        PMID: 8289698     DOI: 10.1016/0306-9877(93)90078-5

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  17 in total

1.  Nonsteroidal anti-inflammatory drugs attenuate amyloid-β protein-induced actin cytoskeletal reorganization through Rho signaling modulation.

Authors:  Patricia Ferrera; Angélica Zepeda; Clorinda Arias
Journal:  Cell Mol Neurobiol       Date:  2017-01-25       Impact factor: 5.046

2.  Neuronal degeneration, synaptic defects, and behavioral abnormalities in tau₄₅₋₂₃₀ transgenic mice.

Authors:  A E Lang; D N Riherd Methner; A Ferreira
Journal:  Neuroscience       Date:  2014-06-18       Impact factor: 3.590

3.  Therapeutics for cognitive aging.

Authors:  Diana W Shineman; Timothy A Salthouse; Lenore J Launer; Patrick R Hof; George Bartzokis; Robin Kleiman; Victoria Luine; Jerry J Buccafusco; Gary W Small; Paul S Aisen; David A Lowe; Howard M Fillit
Journal:  Ann N Y Acad Sci       Date:  2010-04       Impact factor: 5.691

4.  Disturbed neurotransmitter transporter expression in Alzheimer's disease brain.

Authors:  Kevin H Chen; Edmund A Reese; Hyung-Wook Kim; Stanley I Rapoport; Jagadeesh S Rao
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

5.  Disturbed choline plasmalogen and phospholipid fatty acid concentrations in Alzheimer's disease prefrontal cortex.

Authors:  Miki Igarashi; Kaizong Ma; Fei Gao; Hyung-Wook Kim; Stanley I Rapoport; Jagadeesh S Rao
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

6.  Changes in adrenoreceptors in the prefrontal cortex of subjects with dementia: evidence of compensatory changes.

Authors:  P Szot; S S White; J L Greenup; J B Leverenz; E R Peskind; M A Raskind
Journal:  Neuroscience       Date:  2007-02-26       Impact factor: 3.590

7.  Caspase-3 is enriched in postsynaptic densities and increased in Alzheimer's disease.

Authors:  Natalia Louneva; Julia W Cohen; Li-Ying Han; Konrad Talbot; Robert S Wilson; David A Bennett; John Q Trojanowski; Steven E Arnold
Journal:  Am J Pathol       Date:  2008-09-25       Impact factor: 4.307

8.  Retinoic acid attenuates beta-amyloid deposition and rescues memory deficits in an Alzheimer's disease transgenic mouse model.

Authors:  Yun Ding; Aimin Qiao; Ziqing Wang; J Shawn Goodwin; Eun-Sook Lee; Michelle L Block; Matthew Allsbrook; Michael P McDonald; Guo-Huang Fan
Journal:  J Neurosci       Date:  2008-11-05       Impact factor: 6.167

Review 9.  ApoE-dependent plasticity in Alzheimer's disease.

Authors:  Bruce Teter
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

10.  Role of synucleins in Alzheimer's disease.

Authors:  Leslie Crews; Igor Tsigelny; Makoto Hashimoto; Eliezer Masliah
Journal:  Neurotox Res       Date:  2009-06-24       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.